What Peptides Are FDA Approved? The Complete List (2026)

Introduction#

The peptide regulatory landscape shifted dramatically in early 2026. While over 50 peptides remain FDA-approved prescription drugs, the February 27, 2026 announcement by HHS Secretary Robert F. Kennedy Jr. reclassifying 14 peptides from Category 2 back to Category 1 reopened compounding pharmacy access for widely used compounds like BPC-157, Thymosin Alpha-1, and AOD-9604.

This article provides a comprehensive list of FDA-approved peptide drugs organized by therapeutic category, explains the 2026 reclassification and what it means for patient access, and clarifies the distinction between FDA approval, Category 1 compounding status, and research peptides. For a deeper explanation of the Category 1 vs. Category 2 framework, see our FDA Peptide Categories Explained.

For information about which peptides have been banned from compounding, see our guide to FDA-banned peptides. For the broader regulatory picture, see our FDA peptide regulation 2026 overview.

2026 Update: RFK Jr. Peptide Reclassification#

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of 19 peptides previously placed on the FDA's Category 2 restricted list would be moved back to Category 1 status. The announcement was made on the Joe Rogan Experience podcast.

This policy shift restores legal access to these peptides through licensed compounding pharmacies with a physician's prescription.

What Are Category 1 and Category 2?#

The FDA's bulk drug substance evaluation program classifies peptides into two categories:

• Category 1: Substances eligible for compounding under FDA oversight while evaluation continues. Licensed 503A and 503B compounding pharmacies can legally prepare these peptides under a physician's prescription.
• Category 2: Substances flagged for safety concerns and generally not permitted for compounding use. These peptides cannot be legally compounded until their status changes.

Category 1 status does not mean FDA approval. These peptides have not completed the full clinical trial process required for drug approval. They are non-FDA-approved therapeutics that require physician supervision, proper dosing, and ongoing monitoring.

The 14 Peptides Returning to Category 1#

Peptides Remaining on Category 2#

Approximately 5 peptides are expected to remain restricted due to stronger safety concerns or insufficient human safety data:

• Melanotan II -- Associated with cardiovascular and dermatological safety concerns
• GHRP-2 -- Growth hormone-releasing peptide with cortisol/prolactin elevation concerns
• GHRP-6 -- Similar safety profile concerns as GHRP-2
• CJC-1295 with DAC -- Long-acting variant with prolonged half-life raising safety questions
• LL-37 (Cathelicidin) -- Antimicrobial peptide with limited human safety data

What This Means for Patients and Providers#

The reclassification has several practical implications:

1. Compounding pharmacies can resume legally preparing these 14 peptides once the formal FDA rule change is published
2. Physicians can prescribe these compounds through licensed compounding pharmacies
3. Patients gain legal access to peptides like BPC-157 and Thymosin Alpha-1 through proper medical channels
4. Quality standards improve because compounding pharmacies operate under FDA oversight with USP standards

As of early March 2026, the formal FDA rulemaking process has not yet been completed. Until the Category 2 list is officially updated, the legal status of these peptides for compounding remains technically unchanged. For more on how compounding access works, see our compounding pharmacy peptides guide.

What "FDA Approved" Means for Peptides#

An FDA-approved peptide drug has completed the full regulatory approval process, which includes:

1. Preclinical testing: Laboratory and animal studies demonstrating the drug's safety and biological activity
2. Phase 1 clinical trials: Safety and dosing studies in a small number of human volunteers
3. Phase 2 clinical trials: Efficacy and side effect studies in patients with the target condition
4. Phase 3 clinical trials: Large-scale efficacy and safety trials comparing the drug to placebo or existing treatments
5. FDA review: Comprehensive evaluation of all submitted data by the FDA
6. Post-market surveillance: Ongoing safety monitoring after approval

This process typically takes 10-15 years and costs hundreds of millions to billions of dollars. It is the reason relatively few peptides achieve approval despite the large number that show promise in early research.

FDA-Approved Peptide Drugs by Category#

Weight Management and Metabolic Disease#

The GLP-1 receptor agonist class represents the most commercially successful category of peptide drugs, with semaglutide and tirzepatide becoming some of the highest-revenue pharmaceutical products globally.

Growth Hormone Related#

Tesamorelin is notable as the only FDA-approved GHRH analog, specifically approved for reducing visceral adipose tissue in HIV patients with lipodystrophy.

Reproductive Health#

GnRH agonists and antagonists represent one of the most established classes of peptide therapeutics, with applications spanning oncology, reproductive medicine, and endocrinology.

Sexual Health#

PT-141 is the only FDA-approved melanocortin receptor agonist for sexual dysfunction, making it distinct from most other approved peptide drugs in both its target and mechanism.

Bone and Calcium Metabolism#

Gastrointestinal#

Cardiovascular#

Hematology and Immune#

Other Approved Peptide Drugs#

Peptides in Late-Stage Clinical Trials#

Several peptides are in Phase 3 clinical trials and may receive FDA approval in the coming years:

These pipeline peptides represent the next wave of potential approvals, particularly in the metabolic disease space. For more on upcoming peptides, see our clinical trials 2026 article.

FDA-Approved vs. Category 1 Compounding vs. Research Peptides#

The difference in evidence quality between these categories is significant. An FDA-approved peptide has been studied in thousands to tens of thousands of human subjects with rigorous safety monitoring. Category 1 compounding peptides have varying levels of human data but have been deemed safe enough for compounding under physician supervision. Many research peptides have never been formally studied in humans at all.

How to Access FDA-Approved Peptides#

FDA-approved peptide drugs are obtained through:

1. Prescription from a licensed healthcare provider: A physician, nurse practitioner, or physician assistant evaluates whether the peptide is medically appropriate
2. Dispensing from a licensed pharmacy: Retail, specialty, or mail-order pharmacies fill the prescription
3. Insurance coverage: Many approved peptides are covered by health insurance, though coverage varies by plan and indication

How to Access Category 1 Compounding Peptides#

Category 1 peptides like BPC-157 and Thymosin Alpha-1 require:

1. Physician consultation: A licensed provider determines if the peptide is appropriate for your situation
2. Prescription: The provider writes a prescription specifying the peptide, dose, and formulation
3. Compounding pharmacy: A licensed 503A or 503B pharmacy prepares the peptide per the prescription
4. Out-of-pocket payment: Compounded peptides are generally not covered by insurance

For peptide dosing information and calculations, use our dosing calculator. For understanding how long peptides take to produce effects, see our peptide timelines guide.

Key Takeaways#

1. Over 50 peptide drugs have received FDA approval across categories including metabolic disease, reproductive health, bone metabolism, gastrointestinal disorders, and hematology.

2. GLP-1 receptor agonists are the most commercially successful peptide drug class. Semaglutide and tirzepatide have become blockbuster medications for diabetes and obesity.

3. 14 previously restricted peptides are returning to legal compounding access following the February 27, 2026 announcement by HHS Secretary RFK Jr., including BPC-157, Thymosin Alpha-1, AOD-9604, Semax, and Selank.

4. Category 1 compounding status is not the same as FDA approval. Compounding peptides have not completed full clinical trials but are deemed safe enough for preparation by licensed pharmacies under physician oversight.

5. Approximately 5 peptides remain on Category 2, including Melanotan II, GHRP-2, GHRP-6, CJC-1295 with DAC, and LL-37, due to safety concerns or insufficient human data.

6. Several promising peptides are in late-stage clinical trials and may receive full FDA approval in the coming years, including retatrutide, survodutide, and cagrisema.

7. Access to all peptides -- whether FDA-approved or Category 1 -- requires a prescription from a licensed healthcare provider.

Related Peptide Profiles#

Learn more about the peptides discussed in this article:

• Semaglutide Overview and Research Guide
• Tirzepatide Overview and Research Guide
• BPC-157 Overview and Research Guide
• Thymosin Alpha-1 Overview and Research Guide
• AOD-9604 Overview and Research Guide
• Semax Overview and Research Guide
• Selank Overview and Research Guide
• GHK-Cu Overview and Research Guide
• MOTS-c Overview and Research Guide
• KPV Overview and Research Guide
• Gonadorelin Overview and Research Guide
• Triptorelin Overview and Research Guide
• Tesamorelin Overview and Research Guide
• PT-141 Overview and Research Guide